Hot Pharma & Healthcare Issues

Allergan's Aczone gel 7.5%, to treat acne vulgaris, receives US FDA marketing approval

Company Report

 Allergan plc, which is a well-established global pharmaceutical company, revealed that it has been granted approval from the US Food and Drug Administration (FDA) to sell Aczone (dapsone) Ge. It is a 7.5 per cent, topical treatment for acne in patients of age 12 years and older. This gel offers proven efficacy for treating both inflammatory and non-inflammatory acne and has a new concentration of dapsone, which helps in just once-a-day application.

For this gel, a study consisting 4,340 acne patients was done which demonstrated efficacy and tolerability of the gel. The newly FDA-approved gel can be used just once-daily dosing and has a new pump delivery system. As per the executive vice president and president of global R&D brands at Allergan, Mr. David Nicholson, Allergan's dedication to the medical dermatology space, will raise the bar for the company with the efforts to provide an effective acne product to address physician and patient needs.

As per the MD, Director of Dermatology Clinical Research, Division Head of Dermatology at Henry Ford Health System in Michigan and a lead investigator in the studies, Linda Stein Gold, the Aczone Gel, has demonstrated an improvement in patients with acne with 12 years of use and this formulation was well-tolerated.

According to Pharmaion, Pharma and healthcare consultants, foray of Aczone gel will contribute to the market of acne treatment in the future. Moreover, such new acne treatment medications will accelerate research and development in the country. 


Relevant Reports

India Pharmacy Market Opportunities, 2011 - 2021

Pharmaceutical | 22 Aug, 2016News

India is the second most populated country globally, with a total population of 1.3 billion as of 2015. More than 50% of the country’s population is in the age group of <25 years. India accounted for ~20% share in the global

Relevant News